Connor, Clark & Lunn Investment Management (CC&L)’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-26,393
Closed -$11.9K 1604
2025
Q1
$11.9K Sell
26,393
-159,515
-86% -$93.6K ﹤0.01% 1381
2024
Q4
$93.4K Sell
185,908
-5,528
-3% -$4.06K ﹤0.01% 1363
2024
Q3
$173K Sell
191,436
-16,328
-8% -$15.1K ﹤0.01% 1337
2024
Q2
$207K Buy
207,764
+1,521
+0.7% +$1.68K ﹤0.01% 1258
2024
Q1
$305K Buy
206,243
+43,560
+27% +$49.4K ﹤0.01% 1258
2023
Q4
$177K Sell
162,683
-19,878
-11% -$21.8K ﹤0.01% 1278
2023
Q3
$215K Sell
182,561
-70,714
-28% -$96.2K ﹤0.01% 1226
2023
Q2
$357K Buy
253,275
+12,253
+5% +$16.9K ﹤0.01% 1075
2023
Q1
$362K Sell
241,022
-20,880
-8% -$29.1K ﹤0.01% 969
2022
Q4
$306K Sell
261,902
-26,397
-9% -$33.3K ﹤0.01% 974
2022
Q3
$326K Buy
288,299
+152,971
+113% +$225K ﹤0.01% 902
2022
Q2
$214K Buy
135,328
+123,328
+1,028% +$163K ﹤0.01% 920
2022
Q1
$18K Buy
+12,000
New +$18.6K ﹤0.01% 1010
2020
Q4
Sell
-14,601
Closed -$14K 980
2020
Q3
$14K Sell
14,601
-41,940
-74% -$37K ﹤0.01% 907
2020
Q2
$49K Buy
56,541
+5,823
+11% +$5.13K ﹤0.01% 984
2020
Q1
$42K Buy
50,718
+28,568
+129% +$28.5K ﹤0.01% 971
2019
Q4
$20K Buy
+22,150
New +$18.5K ﹤0.01% 906
2019
Q2
Sell
-14,000
Closed -$18K 1037
2019
Q1
$18K Buy
+14,000
New +$17.4K ﹤0.01% 890
2018
Q1
Sell
-111,510
Closed -$210K 761
2017
Q4
$210K Sell
111,510
-12,677
-10% -$27.7K ﹤0.01% 719
2017
Q3
$309K Buy
124,187
+9,601
+8% +$23.8K ﹤0.01% 704
2017
Q2
$316K Buy
114,586
+92,326
+415% +$258K ﹤0.01% 674
2017
Q1
$67K Buy
+22,260
New +$63.2K ﹤0.01% 867

Other funds holding LCTX